Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sun Bean | - |
dc.contributor.author | Kim, Jimin | - |
dc.contributor.author | Huh, Kyungmin | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Kim, Yae-Jean | - |
dc.contributor.author | Joo, Eun-Jeong | - |
dc.contributor.author | Kim, Youn Jeong | - |
dc.contributor.author | Yoon, Young Kyung | - |
dc.contributor.author | Heo, Jung Yeon | - |
dc.contributor.author | Seo, Yu Bin | - |
dc.contributor.author | Jeong, Su Jin | - |
dc.contributor.author | Yu, Su-Yeon | - |
dc.contributor.author | Peck, Kyong Ran | - |
dc.contributor.author | Choi, Miyoung | - |
dc.contributor.author | Yeom, Joon Sup | - |
dc.date.accessioned | 2022-03-01T09:42:28Z | - |
dc.date.available | 2022-03-01T09:42:28Z | - |
dc.date.created | 2021-12-07 | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137361 | - |
dc.description.abstract | Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC ANTIMICROBIAL THERAPY | - |
dc.subject | GUIDELINES | - |
dc.title | Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Young Kyung | - |
dc.identifier.doi | 10.3947/ic.2021.0304 | - |
dc.identifier.scopusid | 2-s2.0-85110351265 | - |
dc.identifier.wosid | 000668613600019 | - |
dc.identifier.bibliographicCitation | INFECTION AND CHEMOTHERAPY, v.53, no.2, pp.395 - 403 | - |
dc.relation.isPartOf | INFECTION AND CHEMOTHERAPY | - |
dc.citation.title | INFECTION AND CHEMOTHERAPY | - |
dc.citation.volume | 53 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 395 | - |
dc.citation.endPage | 403 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002735172 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordAuthor | Anti-SARS-CoV-2 monoclonal antibody | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.